Advancing RAS pathway targeted therapy in NF1-MPNST - effects of SHP2 and CDK4 or CDK6 inhibitors on the tumor and the tumor immune microenvironment

syn53604892

Created By NF Service nf-osi-service

grantDOI: https://reporter.nih.gov/search/jxiS96i18UCvyGMpzGLrgg/project-details/10660326
studyName: Advancing RAS pathway targeted therapy in NF1-MPNST - effects of SHP2 and CDK4 or CDK6 inhibitors on the tumor and the tumor immune microenvironment
dataStatus: Data Pending
initiative: Other
studyLeads: Christine Pratilas
studyStatus: Active
diseaseFocus: Neurofibromatosis type 1
institutions: Johns Hopkins University
fundingAgency: Other
manifestation: MPNST
studyFileviewId: syn53604922
syn53604915
syn53604916
syn53604922
syn53604917

Advancing RAS pathway targeted therapy in NF1-MPNST - effects of SHP2 and CDK4 or CDK6 inhibitors on the tumor and the tumor immune microenvironment page is loading…